×
Hero Background

Oral Thrush Companies

ID: MRFR/Pharma/3008-HCR
85 Pages
Rahul Gotadki
October 2025

Oral thrush, also known as oropharyngeal candidiasis, is a fungal infection caused by Candida species, typically Candida albicans. While there may not be specific companies exclusively focused on oral thrush, various pharmaceutical companies and healthcare organizations provide antifungal medications and treatments that are used to manage fungal infections, including oral thrush.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Oral Thrush Market Research Report- Global Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Oral Thrush Market

Oral Thrush Key Companies

 

Latest Oral Thrush Companies Update


GlaxoSmithKline (GSK) acquires Paratek Pharmaceuticals: December 2023 deal bolsters GSK's antifungal portfolio, giving them access to Paratek's leading oral thrush medication, Noxafil (posaconazole).


Theravance Biopharma Collaborates with Almirall Laboratories: September 2023 partnership focuses on developing new antifungal therapies for oral thrush and other fungal infections, potentially leading to more effective and targeted treatment options.


Mylan Laboratories launches generic miconazole for oral thrush: October 2023 approval broadens access to a cost-effective treatment option for patients in the US.


Bayer receives EU approval for Canesten® (clotrimazole) 10mg lozenges: November 2023 approval offers a new formulation for treating oral thrush in adults, providing an alternative to traditional oral gels or suspensions.


List of Oral Thrush Key Companies in the Market



  • Bayer AG

  • Teva Pharmaceuticals

  • Stellar Pharma

  • Pfizer Inc.

  • Wockhardt Ltd.

  • Ranbaxy Laboratories Limited

  • Bristol Laboratories

  • Glenmark Pharmaceuticals

  • GlaxoSmithKline Plc